Trials / Conditions / Refractory T-Cell Non-Hodgkin Lymphoma

Refractory T-Cell Non-Hodgkin Lymphoma

10 registered clinical trials studyying Refractory T-Cell Non-Hodgkin Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treat NCT07225985	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R NCT05627245	National Cancer Institute (NCI)	Phase 1
Withdrawn	Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428	National Cancer Institute (NCI)	Phase 1
Completed	Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem NCT03259503	M.D. Anderson Cancer Center	Phase 1
Completed	Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin NCT03210662	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor NCT02978625	National Cancer Institute (NCI)	Phase 2
Recruiting	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820	Mayo Clinic	Phase 1
Completed	Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients NCT01921387	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients Wi NCT01701986	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed NCT00860171	Fred Hutchinson Cancer Center	Phase 1